Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the

Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada, BMC Cancer

Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysis - ScienceDirect

Frontiers Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations

Considerations for First-Line Metastatic Melanoma: Which Treatment Is Best?

Updated Data From Clinical Trials on Nivolumab/Ipilimumab in Advanced Melanoma - The ASCO Post

Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies - Kelsey Baron, Justin C Moser, Shiven Patel, Kenneth F Grossmann

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Immunotherapy combination improves PFS in pretreated melanoma

OS of patients with mUM treated with ipilimumab+nivolumab. OS, overall

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Double Trouble: Immunotherapy Doublets in Melanoma—Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma